In a phase II dose-finding trial of 42 adults with progressing desmoid tumours, oral varegacestat caused treatment-related AEs in 97.6% (grade 3 in 21.4%, no serious or grade 4/5 events). The 1.2 mg daily dose gave the largest median week-16 volume reduction (−51.9%).
RCTn = 42
Chugh et al. RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial